Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 35, Issue 10, 2008, Pages 1868-1877

  Good, Stephan ^a   Walter, Martin A ^a   Waser, Beatrice ^c   Wang, Xuejuan ^a   Müller Brand, Jan ^a   Béhé, Martin P ^b   Reubi, Jean Claude ^c   Maecke, Helmut R ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Cholecystokinin; Gastrin; Macrocyclic chelator; Medullary thyroid carcinoma; Minigastrin

Indexed keywords

1 (1 CARBOXY 3 CARBOXYPROPYL) 1,4,7,10 TETRAAZACYCLODODECANE 4,7,10-TRIACETIC ACID MINIGASTRIN 11 IN 111; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID MINIGASTRIN 10 IN 111; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID MINIGASTRIN 11; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID MINIGASTRIN 11 IN 111; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID MINIGASTRIN 9 IN 111; CHELATING AGENT; CHOLECYSTOKININ; CHOLECYSTOKININ RECEPTOR; GASTRIN DERIVATIVE; GASTRIN RECEPTOR; GLUTAMIC ACID; INDIUM 111; IODINE 125; ISOLEUCINE; MACROCYCLIC COMPOUND; METHIONINE; METHIONINE SULFONE; METHIONINE SULFOXIDE; NORLEUCINE; PENTETATE INDIUM IN 111; PENTETIC ACID MINIGASTRIN 10 IN 111; PENTETIC ACID MINIGASTRIN 11 IN 111; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CELL LINE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG STABILITY; DRUG SYNTHESIS; DRUG TARGETING; IC 50; NONHUMAN; RADIOLYSIS; RAT; RECEPTOR AFFINITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; CELL LINE, TUMOR; CHELATING AGENTS; DRUG DELIVERY SYSTEMS; GASTRINS; MACROCYCLIC COMPOUNDS; METABOLIC CLEARANCE RATE; ORGAN SPECIFICITY; PANCREATIC NEOPLASMS; PENTETIC ACID; RADIOPHARMACEUTICALS; RATS; RATS, INBRED LEW; RECEPTOR, CHOLECYSTOKININ B; TISSUE DISTRIBUTION;

EID: 52449093302     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-008-0803-4     Document Type: Article

References (44)

1. SA Wank JR Pisegna A de Weerth 1994 Cholecystokinin receptor family. Molecular cloning, structure, and functional expression in rat, guinea pig, and human Ann N Y Acad Sci 713 49 66
2. JF Rehfeld 2006 The endoproteolytic maturation of progastrin and procholecystokinin J Mol Med 84 544 550
3. F Noble SA Wank JN Crawley J Bradwejn KB Seroogy M Hamon 1999 International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors Pharmacol Rev 51 745 781
4. JC Reubi 2003 Peptide receptors as molecular targets for cancer diagnosis and therapy Endocr Rev 24 389 427
5. JC Reubi B Waser U Laderach C Stettler H Friess F Halter 1997 Localization of cholecystokinin A and cholecystokinin B-gastrin receptors in the human stomach Gastroenterology 112 1197 1205
6. J Reubi B Waser 1996 Unexpected high incidence of cholecystokinin B/gastrin receptors in human medullary thyroid carcinomas Int J Cancer 67 644 647
7. JC Reubi JC Schaer B Waser 1997 Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors Cancer Res 57 1377 1386
8. JC Reubi B Waser 2003 Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting Eur J Nucl Med Mol Imaging 30 781 793
9. M Gotthardt MP Behe D Beuter A Battmann A Bauhofer T Schurrat 2006 Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma Eur J Nucl Med Mol Imaging 33 1273 1279
10. M Gotthardt MP Behe J Grass A Bauhofer A Rinke ML Schipper 2006 Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours Endocr Relat Cancer 13 1203 1211
11. TM Behr N Jenner S Radetzky M Behe S Gratz S Yucekent 1998 Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin Eur J Nucl Med 25 424 430
12. 111In-labeled nonsulfated CCK8 analog: a peptide for CCK-B receptor targeted scintigraphy and radionuclide therapy J Nucl Med 40 2081 2087
13. TM Behr N Jenner M Behe C Angerstein S Gratz F Raue 1999 Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors J Nucl Med 40 1029 1044
14. JC Reubi 2001 CCK receptors in human neuroendocrine tumors: clinical implications Scand J Clin Lab Invest Suppl 234 101 104
15. DJ Kwekkeboom WH Bakker PP Kooij J Erion A Srinivasan M de Jong 2000 Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma Eur J Nucl Med 27 1312 1317
16. JC Reubi HR Maecke EP Krenning 2005 Candidates for peptide receptor radiotherapy today and in the future J Nucl Med 46 67S 75S
17. 99mTc-labeling and in vitro and in vivo evaluation of HYNIC- and (Na-His)acetic acid-modified [d-Glu1]-minigastrin Bioconjug Chem 15 864 871
18. M Behe W Becker M Gotthardt C Angerstein TM Behr 2003 Improved kinetic stability of DTPA-dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives Eur J Nucl Med Mol Imaging 30 1140 1146
19. M Behe TM Behr 2002 Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies Biopolymers 66 399 418
20. 99mTc-labeled minigastrin analogs J Nucl Med 46 1727 1736
21. 111In-DTPAGlu-G-CCK8 for cholecystokinin-B receptor imaging J Nucl Med 45 485 494
22. TM Behr MP Behe 2002 Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies Semin Nucl Med 32 97 109
23. 90Y from cyclic and acyclic ligand-antibody conjugates Nucl Med & Biol 18 469 476
24. KP Eisenwiener P Powell HR Maecke 2000 A convenient synthesis of novel bifunctional prochelators for coupling to bioactive peptides for radiometal labelling Bioorg Med Chem Lett 10 2133 2135
25. 177Lu Eur J Nucl Med Mol Imaging 30 Suppl 2 S319
26. S Good H Maecke 2004 Stability and kinetics of formation of two macrocyclic chelator-conjugates Nuklearmedizin 43 A11
27. A Heppeler S Froidevaux HR Mäcke E Jermann M Béhé P Powell 1999 Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy Chemistry A European Journal 5 1016 1023
28. 111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors Bioconjug Chem 13 530 541
29. J Reubi B Waser J Schaer U Laederach J Erion A Srinivasan 1998 Unsulfated DTPA- and DOTA-CCK analogs as specific high-affinity ligands for CCK-B receptor-expressing human and rat tissues in vitro and in vivo Eur J Nucl Med 25 481 490
30. JC Reubi LK Kvols B Waser DM Nagorney PU Heitz JW Charboneau 1990 Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas Cancer Res 50 5969 5977
31. J Christophe 1994 Pancreatic tumoral cell line AR42J: an amphicrine model Am J Physiol 266 G963 G71
32. D Wild JS Schmitt M Ginj HR Maecke BF Bernard E Krenning 2003 DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals Eur J Nucl Med Mol Imaging 30 1338 1347
33. 0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization? J Nucl Med 46 1561 1569
34. Maecke H, Good S. Radiometals (non-Tc, non-Re) and bifunctional labeling chemistry. In: Vertes A, Nagy S, Klencsar Z, editors. Handbook of nuclear chemistry. Vol. 4. Netherlands; 2003, p. 279-314.
35. 11C]methionine solutions J Radioanal Nucl Chem 256 199 203
36. 90Y-labeled DOTA-biomolecule conjugates using gentisic acid and ascorbic acid Bioconjug Chem 12 554 558
37. S Good H Maecke A Merlo JC Reubi 2004 Development of NK-1 receptor mediated radiopharmaceuticals Nuklearmedizin 43 A7
38. WA Breeman M de Jong DJ Kwekkeboom R Valkema WH Bakker PP Kooij 2001 Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives Eur J Nucl Med 28 1421 1429
39. F Trejtnar M Laznicek 2002 Analysis of renal handling of radiopharmaceuticals Q J Nucl Med 46 181 194
40. 111In-DTPA- octreotide J Nucl Med 46 1696 1700
41. M Behe G Kluge W Becker M Gotthardt TM Behr 2005 Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys J Nucl Med 46 1012 1015
42. 99mTc-HYNIC-Minigastrin: improved in vitro and in vivo properties of a short chain analogue Eur J Nucl Med Mol Imaging 32 Suppl 1 S35
43. M Behe JC Reubi B Nock 2005 Evaluation of a DOTA-minigastrin derivative for therapy and diagnosis for CCK-2 receptor positive tumours Eur J Nucl Med Mol Imaging 32 Suppl 1 S78
44. TM Behr DM Goldenberg W Becker 1998 Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations Eur J Nucl Med 25 201 212